Prognose
Analytikernes gennemsnitlige kursmål er 33,38 € (+6,31 %). Medianen er 35,54 € (+13,18 %).
| Køb |
17 |
| Behold |
7 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Acadia Healthcare sees $200m EBITDA potential from 3,000 new beds
At the Jefferies conference Acadia Healthcare said demand for behavioral health services remains strong while the company works to convert the 3,000 beds opened since 2023 into stable earnings and cash flow. Management cited receivable write-offs, claim denials and start-up losses as near-term headwinds but is confident it can realize about $200 million of incremental EBITDA through accreditations, contract negotiations with payers and higher occupancy. CEO Debbie Osteen promised a “return to basics” and tight execution; one new facility already reached break-even in about a year. The company reports stabilized daily revenues, improved employee retention and expects pressure from receivable write-offs to ease over the course of the year. » Mere på de.investing.com
Acadia Healthcare: KeyBanc raises price target to 40 USD after rising occupancy rates
KeyBanc has raised its price target for Acadia Healthcare to 40 USD, driving the stock on high volume. The reason is growing occupancy rates in the psychiatric clinics and ongoing capacity expansions. Analysts see further substantial upside for the U.S. clinic operator against the backdrop of the mental-health megatrend. » Mere på finanzen.net
Acadia Healthcare hits new 52-week high at $32.82
Acadia Healthcare’s stock rose to a 52-week high of $32.82, gaining 43.92% over the past year. Over the past six months the price increased by 165%, and year-to-date by 123%. Analyst updates, including upgrades from Jefferies and affirmed overweight ratings from KeyBanc, highlight operational improvements under new management and further growth potential. An InvestingPro analysis currently rates the stock as undervalued and sees additional upside potential. » Mere på de.investing.com
Acadia Healthcare sees analyst upgrades but faces bad-debt headwinds
Analysts raised ratings and price targets after Acadia Healthcare reported a strong Q1 and modestly increased 2026 earnings and EBITDA guidance, with Raymond James upgrading to Strong Buy and lifting its target to $39. Cantor Fitzgerald raised its target to $30 but kept a Neutral rating, citing escalating bad debt and claim denials that offset some operational improvements. Acadia is pursuing $200 million in recoveries from underperforming locations while maintaining modest growth, leaving short-term outlooks uncertain despite positive core performance. » Mere på finance.yahoo.com
Acadia Healthcare gets lifted price targets from RBC and Raymond James after Q1 beat
RBC Capital raised its price target on Acadia Healthcare to $31 from $28 and reiterated an Outperform rating after the company beat fiscal Q1 expectations. Raymond James upgraded the stock to Strong Buy, boosting its target to $39 from $25 and modestly raising its 2026 EBITDA and earnings outlook. Raymond James said Acadia can harvest about $200M from underperforming facilities and expects modest underlying growth driving higher estimates and a richer multiple. » Mere på finance.yahoo.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2022 har Acadia Healthcare allerede udloddet 0,72 € i udbytte. Den seneste udlodning fandt sted i februar 2022.
Virksomhedstal
I det seneste kvartal havde Acadia Healthcare en omsætning på 790,42 mio. € og et nettoresultat på 30,45 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 790,42 mio. | 8,93 % |
| Bruttofortjeneste | 152,5 mio. | 78,21 % |
| Nettoresultat | 30,45 mio. | 1,43 % |
| EBITDA | 129,67 mio. | 22,65 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 2,93 mia. € |
Antal aktier | 92,97 mio. |
Højeste/laveste i 52 uger | 36,18 € - 10,42 € |
| Udbytte | Nej |
Beta | 0,63 |
P/E (PE Ratio) | -2,77 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 1,55 |
P/S (PS Ratio) | 0,94 |
Virksomhedsprofil
Acadia Healthcare Company, Inc. udvikler og driver psykiatriske indlæggelsesfaciliteter, behandlingscentre med døgnophold, bofællesskaber, faciliteter til misbrugsbehandling og ambulante adfærdsterapeutiske faciliteter for at imødekomme behovene for adfærdsmæssig sundhedspleje og restitution i lokalsamfund i USA og Puerto Rico. Selskabet driver akutte psykiatriske indlæggelsesfaciliteter, som stabiliserer patienter, der enten udgør en trussel mod sig selv eller andre, og som kræver døgnobservation, daglig intervention og overvågning af psykiatere; samt specialiserede behandlingsfaciliteter, herunder faciliteter til døgnbaseret restitution og spiseforstyrrelser samt omfattende behandlingscentre, der tilbyder en sammenhængende behandling for voksne med afhængighedslidelser og samtidige psykiske lidelser. Selskabet driver også behandlingscentre med døgnophold, som behandler patienter med adfærdsforstyrrelser i et ikke-hospitalsmiljø, herunder udendørsprogrammer, og tilbyder terapeutisk anbringelse for børn og unge med følelsesmæssige lidelser. Pr. 28. februar 2022 drev selskabet et netværk på 228 faciliteter for adfærdsmæssig sundhedspleje med ca. 10.500 senge. Acadia Healthcare Company, Inc. blev grundlagt i 2005 og har hovedkvarter i Franklin, Tennessee.
| Navn | Acadia Healthcare |
| CEO | Debra K. Osteen |
| Hjemsted | Franklin,
tn USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudbydere og -tjenester |
| Børsnotering | 07.12.2015 |
| Medarbejdere | 22.000 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ACHC |
Frankfurt | 7RA.F |
Düsseldorf | 7RA.DU |
München | 7RA.MU |